Skip to content
Clinical Trials – home
ItalyBack to Italy

Clinical trials in Foggia – page 10

269 clinical trials in Foggia, Italy across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

ItalyOur site in ItalyStudi-Clinici.it(opens in a new tab)
Foggia at a glance
269
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

269 trials in Foggia

Open in trial search

Study on the Effectiveness of Infliximab for Children with Inflammatory Bowel Disease

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years
  • Substances:Infliximab
  • Sponsor:Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo

Crohn's disease

Recruiting

Study of Lutikizumab, ABBV-382, and Risankizumab for Adults with Moderate to Severe Crohn's Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:ABBV-8736
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Petosemtamab versus cetuximab plus drug combination as first‑line treatment for adults with metastatic left‑sided colorectal cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Genmab A/S

Asthma

Not yet recruiting

Asthma in adults: beclometasone dipropionate, formoterol fumarate dihydrate, and glycopyrronium bromide compared with beclometasone dipropionate and formoterol fumarate dihydrate

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Beclometasone Dipropionate
  • Sponsor:Chiesi Farmaceutici S.p.A.

Adenocarcinoma pancreas

Not yet recruiting

Low‑dose cyclophosphamide maintenance therapy to prevent recurrence in patients with pancreatic cancer after surgery and neoadjuvant chemotherapy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Cyclophosphamide Monohydrate
  • Sponsor:Associazione Italiana Per Lo Studio Del Pancreas

Phase 2 Study of Inhaled AGMB-447 and Salbutamol Sulfate in Adults with Idiopathic Pulmonary Fibrosis to Evaluate Lung Function, Safety and Tolerability

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Salbutamol Sulfate
  • Sponsor:Agomab Spain S.L.

Multiple sclerosis

Not yet recruiting

Long‑Term Safety and Tolerability of Frexalimab Drug Combination in Adults with Multiple Sclerosis

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Colestyramine
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Adenocarcinoma gastric+1

Not yet recruiting

A Phase 3 Study of ASP2138 Plus Drug Combination in Adults with HER2‑Negative, CLDN18.2‑Positive Advanced Gastric Cancer (First‑Line Treatment)

Registered drug
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Astellas Pharma Global Development Inc.

Osimertinib and drug combination in metastatic non‑small cell lung cancer with targetable genomic driver alterations

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Adagrasib
  • Sponsor:Universita' Degli Studi Di Torino

Safety and efficacy of efimosfermin alfa versus placebo in adults with compensated cirrhosis (stage F4) due to MASH

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Study of efimosfermin alfa versus placebo in adults with compensated cirrhosis from metabolic dysfunction-associated steatohepatitis (MASH)

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Efimosfermin alfa
  • Sponsor:Glaxosmithkline Research & Development Limited

Adenocarcinoma pancreas

Not yet recruiting

First‑Line Study of Zoldonrasib (RMC‑9805) Drug Combination vs Gemcitabine/Nab‑Paclitaxel in Patients with Metastatic KRAS G12D‑Mutated Pancreatic Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Daraxonrasib
  • Sponsor:Revolution Medicines Inc.

Other cities in Italy

The busiest research cities in the country

All 232 cities in Italy

Clinical research in Foggia

What the registry says about research in the country

01 Oncology Research

Innovative clinical trials focusing on metastatic cancers and advanced treatment approaches. Studies include investigations of novel therapies for prostate cancer, colorectal cancer, and various forms of leukemia.

  • Castration-resistant Prostate Cancer
  • Acute Myeloid Leukemia
  • HER2+ Colorectal Cancer

Research emphasizes targeted therapies and combination treatments to improve patient outcomes.

02 Neurological Disorders

Comprehensive studies exploring treatments for multiple sclerosis and neurodegenerative conditions. Research includes evaluation of new therapeutic agents and disease-modifying treatments.

  • Multiple Sclerosis Management
  • Alzheimer's Disease
  • Radiologically Isolated Syndrome

Focus on improving cognitive function and disease progression management.

03 Cardiovascular Health

Advanced research into heart failure prevention and cardiovascular disease management. Studies evaluate new therapeutic combinations and preventive strategies.

  • Heart Failure Prevention
  • Atrial Fibrillation
  • Type 2 Diabetes Cardiovascular Outcomes

Emphasis on reducing cardiovascular events and improving patient outcomes.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.